Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Adding nintedanib to standard of care fails to improve PFS in pleural mesothelioma

Jackey Suen
08 Oct 2018
Prof Giorgio Scagliotti

Adding nintedanib to standard-of-care pemetrexed-cisplatin doublet chemotherapy does not improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM), the phase III LUME-Meso study has shown.

These new findings are in contrast to the study’s phase II results, which showed significant PFS and overall survival (OS) improvements with the addition of nintedanib to standard chemotherapy in this setting.

In the placebo-controlled LUME-Meso study, 458 patients with histologically confirmed epithelioid MPM, no previous systemic therapy, and an Eastern Cooperative Oncology Group performance status of 0–1 were randomized to receive six cycles of pemetrexed-cisplatin doublet chemotherapy plus either nintedanib 200 mg BID or placebo. Patients who did not have disease progression after six cycles of treatment continued to receive maintenance nintedanib or placebo.

“Median PFS by investigator assessment, the primary endpoint of the study, was comparable between the nintedanib group and placebo group [6.8 months vs 7.0 months; hazard ratio (HR), 1.01; 95 percent confidence interval (CI), 0.79 to 1.30; p=0.914]. Similar findings were observed for PFS by independent central review,” reported lead investigator Professor Giorgio Scagliotti of the University of Torino, Italy, who is President of the International Association for the Study of Lung Cancer (IASLC), at the IASLC’s 19th World Conference on Lung Cancer (WCLC 2018) in Toronto, Canada.

In addition, subgroup analysis failed to identify patient groups who might benefit from the addition of nintedanib to doublet chemotherapy.

The secondary endpoint of OS was also similar between the nintedanib group vs placebo group (median, 14.4 months vs 16.1 months; HR, 1.12; 95 percent CI, 0.79 to 1.58; p=0.538).

“Therefore, results of our present study do not support the use of nintedanib in combination with pemetrexed-cisplatin for patients with epithelioid MPM,” said Scagliotti.

Previously, the phase II part of LUME-Meso showed that adding nintedanib to pemetrexed-cisplatin improved PFS and OS in MPM patients, and the effect was particularly evident in those with epithelioid histology. [J Clin Oncol 2017;35:3591-3600] “However, results of our present phase III study did not confirm the phase II findings. The study was discontinued according to the protocol,” highlighted Scagliotti. “The trial reaffirms the need for solid confirmatory studies that are adequately sized to challenge the standard of care in advanced MPM.”

“The side effect profile of nintedanib was consistent with previous nintedanib studies. Patients’ quality of life was not adversely impacted by the addition of nintedanib to chemotherapy,” he added.

“LUME-Meso was well-designed. The two treatment groups were generally well balanced. The outcomes in the placebo group are similar to that observed in previous studies,” commented invited discussant Dr Ross Soo of National University Hospital, Singapore. “Type I error may explain the discordance in PFS between the phase II and phase III findings of LUME-Meso.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.